Exagen Inc. (XGN) 2025 Annual Report: Investor Highlights and Price-Sensitive Information

Overview

Exagen Inc. (Nasdaq: XGN), a medical technology company specializing in diagnostic testing for rheumatic and autoimmune diseases, has released its Annual Report for the fiscal year ended December 31, 2025. The company is primarily focused on developing and commercializing innovative testing products under its AVISE^® brand, which facilitates the diagnosis, prognosis, and monitoring of complex diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Key Financial Metrics and Shareholder Information

• Market Value: As of June 30, 2025, the aggregate market value of Exagen’s common stock held by non-affiliates was approximately \$153.6 million, based on a closing price of \$6.98 per share.
• Shares Outstanding: Total shares of common stock outstanding as of March 6, 2026 stood at 24,053,058.
• SEC Filing Status: Exagen is a non-accelerated filer and qualifies as a smaller reporting company. It is not an emerging growth company, nor a shell company.
• Compliance: The company confirms it has filed all required reports and submitted all Interactive Data Files as per SEC regulations.
• Audit & Controls: Exagen has not filed an attestation report under Section 404(b) of the Sarbanes-Oxley Act, and there were no corrections or restatements related to financial errors in the reporting period.

Business Model and Strategic Focus

Exagen’s primary revenue stream is its portfolio of diagnostic tests, with the flagship AVISE^® CTD test providing comprehensive assessments for connective tissue diseases. The company emphasizes superior clinical utility, rapid turnaround times (typically five business days), and clear test reports for both healthcare providers and patients.

• Revenue Growth & Profitability: Management expects continued revenue growth and positive Adjusted EBITDA in the next 12-18 months, supported by margin expansion and operational efficiencies.
• R&D Commitment: Exagen maintains a thoughtful R&D approach, focusing on projects with proprietary technology, clear reimbursement pathways, and robust clinical evidence. Criteria for new product commercialization include Medicare coverage, value-based pricing, published clinical utility, and medical guideline inclusion.
• Operational Efficiency: Cost improvements are being pursued via core test optimization, minimized overhead, and streamlined salesforce deployment.
• Reimbursement & Coverage: The company continues to leverage clinical studies to facilitate payor coverage and educate insurers on the cost-saving and diagnostic benefits of its products.

Intellectual Property & Competitive Position

Exagen considers its proprietary technologies critical to its business strategy. The company actively seeks patent protection for its testing products and inventions. The AVISE^® portfolio is supported by patents and pending applications, which the management sees as a key competitive advantage.

• Patent Protection: Exagen’s patent strategy covers its research initiatives and product developments. Maintaining and defending these patents, along with in-licensing opportunities, is essential for protecting its market position.
• License Agreements: Exagen has Amended and Restated Exclusive License Agreements in place, further strengthening its intellectual property framework.
• Risk Factors: The report emphasizes that disputes may arise regarding intellectual property rights, and comprehensive risks related to proprietary technology are detailed in the Risk Factors section.

Human Capital Management

Exagen is committed to attracting, retaining, and motivating its workforce, providing competitive benefits and equity incentive plans. The company recognizes the importance of optimizing human capital as it grows and plans to refine hiring, development, and retention practices.

Forward-Looking Statements and Non-GAAP Metrics

The company uses Adjusted EBITDA as a non-GAAP measure to provide investors with additional insights into operational performance. Management cautions that forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from projections due to unpredictable factors, some of which may be beyond the company’s control.

• Adjusted EBITDA Definition: Net loss adjusted for interest income/expense, income tax, depreciation/amortization, stock-based compensation, and certain non-cash or unusual items.
• Risk Disclosure: Investors are advised to review the full set of financial statements and not rely solely on non-GAAP measures.

Potential Price-Sensitive Information

• Guidance for Continued Revenue Growth and Positive Adjusted EBITDA: Management’s expectation of sustained growth and profitability in the coming 12-18 months is likely to be viewed positively by investors and could impact share price.
• Operational Efficiency Initiatives: Ongoing strategies to expand gross margins and reduce operating expenses may enhance future profitability and shareholder value.
• Patent and Intellectual Property Developments: Robust IP protection and licensing agreements are critical for maintaining market leadership and may affect competitive dynamics.
• No Material Financial Errors or Restatements: The absence of financial corrections or restatements supports confidence in financial reporting integrity.
• Human Capital Investments: Continued focus on employee motivation, retention, and development could strengthen organizational performance and innovation.

Conclusion

Exagen Inc.’s 2025 Annual Report presents several positive developments and strategic initiatives that may be significant for shareholders and potentially influence the company’s share price. Investors should closely monitor the company’s execution of its growth strategy, R&D pipeline, patent protections, and operational improvements, as these factors are likely to shape future financial performance and market valuation.

Disclaimer: This article is based on Exagen Inc.’s Annual Report for 2025 and is intended for informational purposes only. It does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, and investors should conduct their own due diligence before making investment decisions. The author assumes no responsibility for any actions taken based on this information.

View EXAGEN INC. Historical chart here